{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:13:49Z","timestamp":1792782829118,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen","id":[{"id":"https:\/\/ror.org\/05591te55","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Central venous catheters (CVCs) are a cornerstone for effective supportive therapy in patients with AML undergoing remission induction chemotherapy. While peripherally inserted central catheters (PICCs) are increasingly used as an alternative to centrally inserted central catheters (CICCs), real world data on their implications on AML and supportive therapy remain limited. This study aimed to compare infectious and non-infectious complications of PICCs vs. CICCs in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a single-center retrospective cohort study of 116 AML patients receiving induction chemotherapy between June 2019 and March 2024. Patients received either a PICC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200959) or a CICC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200957). Catheter-related complications were analyzed as incidence rates per 1000 catheter days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PICCs had a longer median dwell time than CICCs (16 vs.\u202f11\u00a0days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). Catheter-related bloodstream infection (CRBSI) rates were low and similar (2.8 vs.\u202f2.6\/1000 catheter days,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.93). Exit site infections were significantly lower in the PICC group (7.4 vs.\u202f23.1\/1000 catheter days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). Bleeding events occurred more frequently in PICCs (13.9 vs.\u202f6.4\/1000 catheter days,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.14) but were mostly minor. More patients in the CICC group received at least one platelet transfusion before insertion (36.8% vs. 16.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). Mechanical complications and symptomatic thromboses were rare in both groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PICCs were associated with longer dwell times and fewer local infections, without increased risk of CRBSIs or thrombosis. These findings suggest that PICCs may help optimize supportive care in clinically stable patients undergoing AML induction chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-11146-3","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:48:06Z","timestamp":1787939286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Catheter-related complications in AML remission induction chemotherapy: a retrospective comparison of PICCs and CICCs"],"prefix":"10.1007","volume":"34","author":[{"given":"S.","family":"Ehrlich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Aytan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Eufinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Doedens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Subklewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"B\u00fccklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"11146_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM et al (2025) Acute myeloid leukemia management and research in 2025. CA Cancer J Clin 75:46\u201367. https:\/\/doi.org\/10.3322\/caac.21873","journal-title":"CA Cancer J Clin"},{"key":"11146_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41375-022-01786-9","volume":"37","author":"CS Walti","year":"2023","unstructured":"Walti CS, Halpern AB, Xie H et al (2023) Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia 37:298\u2013307. https:\/\/doi.org\/10.1038\/s41375-022-01786-9","journal-title":"Leukemia"},{"key":"11146_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00277-020-04286-x","volume":"100","author":"B B\u00f6ll","year":"2021","unstructured":"B\u00f6ll B, Schalk E, Buchheidt D et al (2021) Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 100:239\u2013259. https:\/\/doi.org\/10.1007\/s00277-020-04286-x","journal-title":"Ann Hematol"},{"key":"11146_CR4","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1007\/s00520-019-05276-0","volume":"28","author":"D Mielke","year":"2020","unstructured":"Mielke D, Wittig A, Teichgr\u00e4ber U (2020) Peripherally inserted central venous catheter (PICC) in outpatient and inpatient oncological treatment. Support Care Cancer 28:4753\u20134760. https:\/\/doi.org\/10.1007\/s00520-019-05276-0","journal-title":"Support Care Cancer"},{"key":"11146_CR5","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.1016\/j.clml.2018.12.008","volume":"19","author":"M Picardi","year":"2019","unstructured":"Picardi M, Della Pepa R, Cerchione C et al (2019) A frontline approach with peripherally inserted versus centrally inserted central venous catheters for remission induction chemotherapy phase of acute myeloid leukemia: a randomized comparison. Clin Lymphoma Myeloma Leuk 19:e184\u2013e194. https:\/\/doi.org\/10.1016\/j.clml.2018.12.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"11146_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072147","author":"M Picardi","year":"2023","unstructured":"Picardi M, Giordano C, Della Pepa R et al (2023) Intravascular complications of central venous catheterization by insertion site in acute leukemia during remission induction chemotherapy phase: lower risk with peripherally inserted catheters in a single-center retrospective study. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15072147","journal-title":"Cancers (Basel)"},{"key":"11146_CR7","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00277-016-2798-4","volume":"95","author":"M Refaei","year":"2016","unstructured":"Refaei M, Fernandes B, Brandwein J et al (2016) Incidence of catheter-related thrombosis in acute leukemia patients: a comparative, retrospective study of the safety of peripherally inserted vs. centrally inserted central venous catheters. Ann Hematol 95:2057\u20132064. https:\/\/doi.org\/10.1007\/s00277-016-2798-4","journal-title":"Ann Hematol"},{"key":"11146_CR8","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","volume":"96","author":"WJ Heinz","year":"2017","unstructured":"Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96:1775\u20131792. https:\/\/doi.org\/10.1007\/s00277-017-3098-3","journal-title":"Ann Hematol"},{"key":"11146_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/annonc\/mdt545","volume":"25","author":"M Hentrich","year":"2014","unstructured":"Hentrich M, Schalk E, Schmidt-Hieber M et al (2014) Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. Ann Oncol 25:936\u2013947. https:\/\/doi.org\/10.1093\/annonc\/mdt545","journal-title":"Ann Oncol"},{"key":"11146_CR10","doi-asserted-by":"publisher","first-page":"1200.e1201","DOI":"10.1016\/j.cmi.2023.05.025","volume":"29","author":"N Buetti","year":"2023","unstructured":"Buetti N, Ruckly S, Souweine B et al (2023) Risk of infections in intravascular catheters in situ for more than 10 days: a post hoc analysis of randomized controlled trials. Clin Microbiol Infect 29:1200.e1201-1200.e1205. https:\/\/doi.org\/10.1016\/j.cmi.2023.05.025","journal-title":"Clin Microbiol Infect"},{"key":"11146_CR11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1017\/ice.2017.92","volume":"38","author":"E Schalk","year":"2017","unstructured":"Schalk E, Biehl LM, F\u00e4rber J et al (2017) Determination of a cutoff time point for prophylactic exchange of central venous catheters for prevention of central venous catheter-related bloodstream infections in patients with hematological malignancies. Infect Control Hosp Epidemiol 38:888\u2013889. https:\/\/doi.org\/10.1017\/ice.2017.92","journal-title":"Infect Control Hosp Epidemiol"},{"key":"11146_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151990","volume":"11","author":"GI Perez Perez","year":"2016","unstructured":"Perez Perez GI, Gao Z, Jourdain R et al (2016) Body site is a more determinant factor than human population diversity in the healthy skin microbiome. PLoS ONE 11:e0151990. https:\/\/doi.org\/10.1371\/journal.pone.0151990","journal-title":"PLoS ONE"},{"key":"11146_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00277-010-1005-2","volume":"89","author":"D Luft","year":"2010","unstructured":"Luft D, Schmoor C, Wilson C et al (2010) Central venous catheter-associated bloodstream infection and colonisation of insertion site and catheter tip. What are the rates and risk factors in haematology patients? Ann Hematol 89:1265\u20131275. https:\/\/doi.org\/10.1007\/s00277-010-1005-2","journal-title":"Ann Hematol"},{"key":"11146_CR14","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa2214322","volume":"388","author":"FLF van Baarle","year":"2023","unstructured":"van Baarle FLF, van de Weerdt EK, van der Velden W et al (2023) Platelet transfusion before CVC placement in patients with thrombocytopenia. N Engl J Med 388:1956\u20131965. https:\/\/doi.org\/10.1056\/NEJMoa2214322","journal-title":"N Engl J Med"},{"key":"11146_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/s0140-6736(13)60592-9","volume":"382","author":"V Chopra","year":"2013","unstructured":"Chopra V, Anand S, Hickner A et al (2013) Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis. Lancet 382:311\u2013325. https:\/\/doi.org\/10.1016\/s0140-6736(13)60592-9","journal-title":"Lancet"},{"key":"11146_CR16","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.2217\/fon-2022-0706","volume":"18","author":"D Huggar","year":"2022","unstructured":"Huggar D, Knoth RL, Copher R et al (2022) Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy. Future Oncol 18:3609\u20133621. https:\/\/doi.org\/10.2217\/fon-2022-0706","journal-title":"Future Oncol"},{"key":"11146_CR17","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1080\/10428194.2019.1594213","volume":"60","author":"P Fassbind","year":"2019","unstructured":"Fassbind P, Jeker B, Mueller BU et al (2019) Improved survival rates of AML patients following admission to the intensive care unit. Leuk Lymphoma 60:2423\u20132431. https:\/\/doi.org\/10.1080\/10428194.2019.1594213","journal-title":"Leuk Lymphoma"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11146-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11146-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11146-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:51:26Z","timestamp":1790322686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11146-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["11146"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11146-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the 1964 Declaration of Helsinki and its later amendments. Approval was granted by the Ethics Committee of the LMU University (23\u20130091).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was not required for this retrospective analysis of anonymized clinical routine data, in accordance with local regulations and the approval of the institutional ethics committee.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.S. (Seidensticker) reports lecture honoraria from Cook\u202fMedical, Siemens\u202fHealthineers, Astra\u202fZeneca, Bayer, Roche, Balt, Boston\u202fScientific, LIAM, and Sirtex\u202fMedical. He has served on advisory boards for Siemens\u202fHealthineers, Cook\u202fMedical, Cook\u202fAdvanced\u202fTechnologies, Roche, and Sirtex\u202fMedical, and received research funding from Sirtex\u202fMedical, Astra\u202fZeneca, Boston\u202fScientific, and Bayer. The other authors declare that there is no financial or non-financial conflict of interest relevant to the content of this article.","order":3,"name":"Ethics","label":"<b>Competing interests<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"906"}}